-transparent.png){kind=logo}
A woman with myasthenia gravis and a thymoma did not respond sufficiently to thymectomy. She was treated with 6-mercaptopurine. Withdrawal of this treatment was several times followed by an aggravation of myasthenic symptoms. After more than 12 1/2 years treatment she developed Ph1-positive chronic myeloid leukemia (CML). No other case of CML following immunosuppressive treatment has been described. Because the therapeutic agent is potentially leukemogenic, the possibility cannot be definitely excluded that the development of CML is not a mere coincidence.
Related Publications
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
April 2007,
Annals of oncology : official journal of the European Society for Medical Oncology,
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
April 2014,
Hematology reports,
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
January 2002,
Journal of clinical apheresis,
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
February 1990,
Postgraduate medical journal,
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
August 1968,
Blood,
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
December 1970,
Lyon medical,
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
July 1966,
Minnesota medicine,
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
June 1961,
Deutsche medizinische Wochenschrift (1946),
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
September 2017,
Journal of mathematical biology,
J Wanders, and
A R Wattendorff, and
L J Endtz, and
J J den Nijs, and
C H Leeksma
January 1987,
Annals of the New York Academy of Sciences,
